Profil bibliographique

Al-Ola Abdallah

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

20Publications signalées

219Citations signalées

4Affiliations récentes

Institutions déclarées

Research Medical Center The University of Kansas Cancer Center University of Kansas Medical Center University of Missouri–Kansas City

Domaines associés

Multiple Myeloma Research and TreatmentsCAR-T cell therapy researchProtein Degradation and InhibitorsPeptidase Inhibition and AnalysisBiosimilars and Bioanalytical Methods

Publications récentes

2025 conference-abstractOpenAlex

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Saad Z. Usmani, Michał Mielnik, Aránzazu Alonso Alonso, Al-Ola Abdallah et autres

0 citationsBlood

2025 conference-abstractOpenAlex

Efficacy of tocilizumab prophylaxis in preventing cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome: A systematic review and meta-analysis

Moazzam Shahzad, Hafiz Muhammad Asif Javed, Hafsa Shahid, Anas Zayad et autres

0 citationsBlood

2025 articleOpenAlex

Optimizing Belantamab Mafodotin Doses for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the DREAMM-9 Study

Saad Z. Usmani, Michał Mielnik, Mamta Garg, Irwindeep Sandhu et autres

1 citationClinical Lymphoma Myeloma & Leukemia

2025 articleOpenAlex

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Vânia Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova et autres

25 citationsThe Lancet Oncology

2025 articleOpenAlex

Real-World Practice in the Management of Transplant-Eligible Newly Diagnosed Multiple Myeloma: A US-Based Cross-Sectional National Survey

Hossam M. Ali, Zainab Yusufali Motiwala, Yara Shatnawi, Jack Khouri et autres

1 citationClinical Lymphoma Myeloma & Leukemia

Accès ouvert 2025 articleOpenAlex

Neurologic Adverse Events Associated With T-cell Engager Therapy in Multiple Myeloma: A Pharmacovigilance Study

Muhammad Atif Khan, Faiza Humayun Khan, Sohaib Irfan, Zahra Mahmoudjafari et autres

0 citationsCureus

2025 articleOpenAlex

The Impact of Sponsors on Development of Clinical Research in Multiple Myeloma and AL Amyloidosis: An In-Depth Analysis

Anas Zayad, Nausheen Ahmed, Zahra Mahmoudjafari, Barry Skikne et autres

1 citationClinical Lymphoma Myeloma & Leukemia

Accès ouvert 2025 articleOpenAlex

Talquetamab in heavily pretreated patients with multiple myeloma, including BCMA-refractory

Andrew Vegel, Bradley T. Loeffler, Jonathan Lochner, Reed Friend et autres

6 citationsBlood Immunology & Cellular Therapy

Accès ouvert 2025 articleOpenAlex

A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma

Rachel Dileo, Prerna Mewawalla, Kalaivani Babu, Yue Yin et autres

6 citationsBlood Cancer Journal

Accès ouvert 2025 articleOpenAlex

Incidence and Severity of Cytopenias Secondary to CD19-Targeted CAR-T Cell Therapy: A Systemic Review and Meta-Analysis

Moazzam Shahzad, Abhinav Vyas, Muhammad Kashif Amin, Dania Kaur et autres

1 citationTransplantation and Cellular Therapy

2024 conference-abstractOpenAlex

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Vânia Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova et autres

14 citationsBlood

2024 conference-abstractOpenAlex

Incidence and Severity of Cytopenias Secondary to CD19-Targeted CAR-T Cell Therapy: A Systemic Review and Meta-Analysis

Moazzam Shahzad, Abhinav Vyas, Muhammad Kashif Amin, Dania Kaur et autres

0 citationsBlood

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.